Funding Round
Alto Neuroscience raises $45M Series C following Phase 2 PTSD trial success
Fierce Biotech4/18/2026·04/18/26🌐 USA
Summary
Alto Neuroscience closed a $45M Series C led by Novo Holdings, with General Atlantic and Lux Capital participating, immediately following positive Phase 2 data for ALTO-300 in PTSD showing 68% response rate in veterans. The funds will support Phase 3 trial initiation for PTSD and a new Phase 2 trial in treatment-resistant depression.
Why it matters
Novo Holdings leading the round — typically a late-stage life science investor — signals that Alto's PTSD data is compelling enough to attract traditionally risk-averse pharma-oriented capital. This validates the precision psychiatry platform thesis beyond a single asset.
#Industry#Neuropharmacology#Neurostimulation#PTSD#Phase 2#USA#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in